ArticleAntimicrobial agents and chemotherapy2015
High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Interventions to reduce Staphylococcus aureus in the management of eczema.The Cochrane database of systematic reviews · 2019Pooled it
- Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.Clinical and translational medicine · 2022Trial
- Molecular Characterization of Nasal Methicillin-Resistant Staphylococcus aureus Isolates Showing Increasing Prevalence of Mupirocin Resistance and Associated Multidrug Resistance following Attempted Decolonization.Antimicrobial agents and chemotherapy · 2018Trial
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.JAMA dermatology · 2018Trial
- Staphylococcal Scalded Skin Syndrome in a Tertiary Pediatric Hospital over an 11-Year Period.Children (Basel, Switzerland) · 2026Article
- Increase in imported mupirocin-resistantNew microbes and new infections · 2026Article
- The combination of mupirocin and Kayvirus broadens the decolonization effect against Staphylococcus aureus.Applied microbiology and biotechnology · 2026Article
- Silver sulfadiazine in modern dermatology.Dermatology online journal · 2025Review
- Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials.Journal of clinical medicine · 2025Review
- Clinical relevance of topical antibiotic use in co-selecting for multidrug-resistantAntimicrobial agents and chemotherapy · 2023Article
- New therapeutic applications of ozenoxacin in superficial skin infections.Dermatology reports · 2022Article
- Article
- Microbial manipulation in atopic dermatitis.Clinical and translational medicine · 2022Article
- New update on molecular diversity of clinical Staphylococcus aureus isolates in Iran: antimicrobial resistance, adhesion and virulence factors, biofilm formation and SCCmec typing.Molecular biology reports · 2022Article
- Non-bullous Impetigo: Incidence, Prevalence, and Treatment in the Pediatric Primary Care Setting in Italy.Frontiers in pediatrics · 2022Article
- Mupirocin-ResistantBioMed research international · 2022Article
- Feasibility Study for a Randomised Controlled Trial for the Topical Treatment of Impetigo in Australian General Practice.Tropical medicine and infectious disease · 2021Article
- Article
- Prevalence and Risk Factors of Mastitis and Isolation, Identification and Antibiogram ofInfection and drug resistance · 2021Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical mupirocin is used widely to treat skin and soft tissue infections and to eradicate nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). Few studies to date have characterized the rates of S. aureus mupirocin resistance in pediatric populations. We retrospectively studied 358 unique S. aureus isolates obtained from 249 children seen in a predominantly outpatient setting by the Division of Pediatric Dermatology at a major academic center in New York City between 1 May 2012 and 17 September 2013. Mupirocin resistance rates and the associated risk factors were determined using a logistic regression analysis. In our patient population, 19.3% of patients had mupirocin-resistant S. aureus isolates at the time of their first culture, and 22.1% of patients with S. aureus infection had a mupirocin-resistant isolate at some time during the study period. Overall, 31.3% of all S. aureus isolates collected during the study period were resistant to mupirocin. Prior mupirocin use was strongly correlated (odds ratio [OR] = 26.5; P = <0.001) with mupirocin resistance. Additional risk factors for mupirocin resistance included methicillin resistance, atopic dermatitis (AD), epidermolysis bullosa (EB), immunosuppression, and residence in northern Manhattan and the Bronx. Resistance to mupirocin is widespread in children with dermatologic complaints in the New York City area, and given the strong association with mupirocin exposure, it is likely that mupirocin use contributes to the increased resistance. Routine mupirocin testing may be important for MRSA decolonization strategies or the treatment of minor skin infections in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.